Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
CStone Pharmaceuticals Co Ltd (CStone Pharmaceuticals) is a biopharmaceutical company focused on the research, development, and commercialization of therapies for oncology, immunology, inflammation, and other disease areas. The company's products include avapritinib for gastrointestinal stromal tumors and systemic mastocytosis, and pralsetinib for non-small cell lung cancer and thyroid cancer. Its pipeline products include sugemalimab for non-small cell lung cancer, gastric or gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory extranodal NK/T-cell lymphoma; CS1002 for solid tumors; CS2009 and CS1012 for solid tumors; CS5001 for solid tumors and hematologic malignancies; multiple antibody-drug conjugates for solid tumors; and immunology and inflammation candidates including CS2013, CS2015, CS1016, and CS2016. CStone Pharmaceuticals is headquartered in Suzhou, Jiangsu, China.
Headquarters
China
Address
1000 Zhangheng Road Bldg 25, Pudong New District, Suzhou, Jiangsu, 200126
Website
www.cstonepharma.com
Telephone
86 21 60335000
No of Employees
147
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
2616 (HKG)
Revenue (2024)
$37.5M
-33.8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-379.1%
(2024 vs 2023)
Market Cap*
$955.1M
Net Profit Margin (2024)
XYZ
-623.7%
(2024 vs 2023)
* As of and is in US$
CStone Pharmaceuticals Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Avapritinib | AYVAKIT |
| Pralsetinib | GAVRETO |
| Pipeline Drugs: | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In January, the company partnered with SteinCares to commercialize sugemalimab in 10 Latin American countries, including Brazil, Mexico, and Argentina. |
| 2024 | Contracts/Agreements | In November, the company partnered with Pharmalink to commercialize Sugemalimab in the Middle East and North Africa. |
| 2024 | Contracts/Agreements | In July, the company signed an agreement with Jiangsu Hengrui Medicine Co., Ltd. (Hengrui Medicine) to grant Hengrui Medicine the promotion rights for the precision medicine Tajiva ( afatinib tablets) in mainland China. |
Competitor Comparison
| Key Parameters | CStone Pharmaceuticals Co Ltd | Akeso Inc | Everest Medicines Ltd | Lee's Pharmaceutical Holdings Ltd | Mabpharm Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | Hong Kong | China |
| City | Suzhou | Zhongshan | Shanghai | Hong Kong City | Taizhou |
| State/Province | Jiangsu | Guangdong | Shanghai | - | Jiangsu |
| No. of Employees | 147 | 4,082 | 1,290 | 1,137 | 394 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Wei Li | Chairman | Executive Board | 2023 | 54 |
| Jianxin Yang, M.D., Ph.D | Chief Executive Officer; Director; President - Research and Development | Executive Board | 2023 | 62 |
| Weicong Ni | Chief Financial Officer; Secretary | Senior Management | 2018 | 35 |
| Yinghua Zhang | Chief Operating Officer | Senior Management | 2026 | 47 |
| Qingmei Shi, M.D., Ph.D. | Chief Medical Officer | Senior Management | 2019 | 50 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer